Tina Liedtky: Thermo Fisher Scientific Launches New Test to Help Guide Tacrolimus Dosing
Tina Liedtky, President of the Transplant Diagnostics Division at Thermo Fisher Scientific, shared a post on LinkedIn:
“In transplant medicine, every patient is unique. And healthcare teams need tools that enable them to provide personalized care.
To this end, I am excited to share that, today, Thermo Fisher Scientific launched a new laboratory developed test to help inform clinicians on dosing tacrolimus, a commonly prescribed immunosuppressive drug that can help lower the risk of transplant rejection.
The right tacrolimus dose will vary from patient to patient.
With the new TacroType Pharmacogenetic Test, clinicians can better understand how their patient is likely to metabolize tacrolimus and respond to certain therapies.
This pharmacogenetic information is invaluable.
Learn more about what the new TacroType Pharmacogenetic Test means for patient care by reading the press release.”
Stay updated with Hemostasis Today.
-
Sep 1, 2026, 18:13Ramsha Batool: Chemotherapy-Induced Anemia Impacts Quality of Life in Breast Cancer
-
Sep 1, 2026, 18:09Natalya Shynhera: Using Anemia to Teach Medical English in Real Clinical Practice
-
Sep 1, 2026, 18:06Wei Du: New Therapeutic Potential for PARP Inhibitors in MLL-Rearranged Leukemia
-
Sep 1, 2026, 18:03Tobias Tichelbäcker: PRAGUE-26 Shows Catheter Lysis Beats Anticoagulation Without Ultrasound
-
Sep 1, 2026, 18:00Baptiste Thibault: My First Publication as First Author on Ionized Calcium Monitoring Before Citrate-CRRT
-
Sep 1, 2026, 17:51Nadezhda Vasilyeva: Shifting the Boundaries of Acute Ischemic Stroke Management
-
Sep 1, 2026, 17:49Malik Ghannam: Recent Venous Thrombosis Risk Factors May Help Explain Cryptogenic Stroke in Young Adults
-
Sep 1, 2026, 17:42Rishabh Jain: Renal Artery FMD Is Managed With Balloon Angioplasty Alone
-
Sep 1, 2026, 17:42Caitlin R: The Brain’s Need to Find Patterns